Dexcom
The fund will be zeroing in on sensing tech, data analytics, remote patient monitoring and population health.
The company attributes volume growth, new patient additions and increasing awareness of real-time continuous glucose monitoring to its revenue growth.
In a J P. Morgan virtual talk, CEO Jason Gorevic said the programs have either already kicked off or will be launching later this year.
Also: Dexcom continues to make strides, while iRhythm Technologies takes a hit in Q2.
Dexcom President and CEO Kevin Sayer is “incredibly proud” of what the company is calling “resilient growth” in the second quarter of 2020, according to an earnings call on Tuesday.
Some of Dexcom’s G6 applicators were getting stuck to the wearable CGM, but the company said it has worked to remedy this issue.
The executives also share details about what patients can expect from the G7 next year.
Also: Kore and Dexcom prepare the G6 CGM for remote patient-monitoring; Tyto Care tackles Europe with santé24 integration and deployment.
Also Fitbit struggles as it waits to be acquired by Google, and Livongo sees strong growth.